11 research outputs found
EVALUATION OF THE DEGREE OF STENOTIC PROCESS (STENOSIS) OF THE SPINAL CANAL AT THE LUMBAR LEVEL
In the article the evaluation of the degree of stenotic process in the spinal canal in 48 patients with stenosis of the spine judging by the morphometric measurements of vertebrae, dural sac and spinal canal. The authors improved and supplemented the morphometric technique of measurements of a number of parameters, on their basis the mathematical model was worked out and mathematical calculations to determine the coefficient of stenotic process in the spinal canal at the lumbar level were hold (Zn). The diagnostics of stenosis of spinal canal basing on worked out clinic ray criteria using mathematical modeling can help more complete diagnostics and evaluation of the degree of stenotic process of the spinal canal at the lumbar level and let choose appropriate prevention and treatment of this pathology. The calculated ratio of stenotic process (Zn) and its values let clinicians choose tactics of conservative or surgical treatment in time and choose the way of prevention of complications of stenotic process of the spinal canal
Π‘Π²ΡΠ·Ρ ΠΈΠ½Π΄Π΅ΠΊΡΠΎΠ² ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ Ρ ΠΏΠ΅ΡΠΈΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΠΌ ΡΡΠ°ΡΡΡΠΎΠΌ ΠΈ Π±Π»ΠΈΠΆΠ°ΠΉΡΠΈΠΌ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΎΠΌ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ ΡΠ³Π»Π΅Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° ΠΈ Π½ΠΎΡΠΌΠΎΠ³Π»ΠΈΠΊΠ΅ΠΌΠΈΠ΅ΠΉ, ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π°ΡΡΠΈΡ ΡΡ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠΌΡ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ
Highlights. Patients with coronary artery disease undergoing coronary artery bypass grafting have a high prevalence of type 2 diabetes mellitus and prediabetes. The frequency of postoperative stroke and hospital stay is significantly higher in patients with impaired carbohydrate metabolism.Insulin resistance markers are associated with a variety of perioperative characteristics, but according to multivariate analysis, only free fatty acids and HOMA-IR were independent predictors of hospitalacquired complications and long-term hospital stayAim. To analyze insulin resistance markers and their association with the preoperative outcome and in-hospital complications of coronary bypass grafting (CABG) in patients with type 2 diabetes mellitus (DM 2), prediabetes and normoglycemia.Methods. The study included 383 consecutive patients undergoing CABG at the same center. Glycemic status, free fatty acids (FFA), fasting insulin, glucose, lipid profile of all patients were determined before surgery and the following insulin resistance indices (IR) were calculated: HOMA-IR (Homeostasis Model Assessment of Insulin Resistance), QUICKI (Quantitative Insulin Sensitivity Check Index), Revised QUICKI, McAuley. Patients were divided into 2 groups: the group that included patients with carbohydrate metabolism disorders (CMD), type 2 diabetes mellitus and prediabetes (n = 192), and the group of patients without CMD (n = 191). Perioperative characteristics of patients, postoperative complications and their association with insulin resistance markers were analyzed.Results. FFA and calculated indices of insulin resistance such as HOMA-IR, QUICKI, RevisedQUICKI, and McAuley correlated with the following perioperative characteristics: the duration of surgical intervention and cardiopulmonary bypass, lipid levels, coagulation index, left ventricular dimension and myocardial diastolic function, etc. The analysis of in-hospital complications revealed that the frequency of postoperative stroke (p = 0.044) and hospital stay after CABG >30 days (p = 0.014) was significantly higher in patients with CMD. According to the results of multivariate analysis, the predictors of the composite endpoint (hospital stay after CABG>10 days and/or significant perioperative complication) were as follows: female sex (odds ratio (OR) 2.862, 95% confidence interval (CI) 1.062-7.712, p = 0.036); age (OR 1.085, 95%CI 1.027β1.147, p = 0.003); duration of cardiopulmonary bypass (OR 1.146, 95%CI 1.008β1.301, p = 0.035); body mass index (OR 1.125, 95% CI 1.035β1.222, p = 0.005), left atrial dimension (OR 5.916 95% CI 2.188β15.996, p<0.001); any CMD (OR 1.436, 95%CI 1.029β2.003, p = 0.032), type 2 DM (OR 2.184, 95%CI 1.087β4.389, p = 0.027), FFA levels (OR 5.707, 95%CI 1.183β27.537, p = 0.029) and HOMAβIR index (OR 1.164, 95%CI 1.025β1.322, p = 0.019).Conclusion. FFA, HOMA-IR, QUICKI, Revised-QUICKI, and McAuley correlate with a variety of perioperative characteristics of patients undergoing CABG, but multivariate analysis revealed that only FFA levels and the HOMA-IR can be used as predictors of in-hospital complications and prolonged hospital stay.ΠΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ. Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΡΡ ΡΠ΅ΡΠ΄ΡΠ°, ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π°ΡΡΠΈΡ
ΡΡ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠΌΡ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ, Π²Π΅Π»ΠΈΠΊΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ ΡΠ°Ρ
Π°ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ°Π±Π΅ΡΠ° 2-Π³ΠΎ ΡΠΈΠΏΠ° ΠΈ ΠΏΡΠ΅Π΄ΠΈΠ°Π±Π΅ΡΠ°. Π§Π°ΡΡΠΎΡΠ° ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΈΠ½ΡΡΠ»ΡΡΠ° ΠΈ ΠΏΡΠ΅Π±ΡΠ²Π°Π½ΠΈΡ Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ΅ Π·Π½Π°ΡΠΈΠΌΠΎ Π²ΡΡΠ΅ Ρ Π»ΠΈΡ Ρ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ ΡΠ³Π»Π΅Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π°.ΠΠ°ΡΠΊΠ΅ΡΡ ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½ΡΠ΅ ΡΠ²ΡΠ·ΠΈ ΡΠΎ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ, Π½ΠΎ Π² ΠΌΠ½ΠΎΠ³ΠΎΡΠ°ΠΊΡΠΎΡΠ½ΠΎΠΌ Π°Π½Π°Π»ΠΈΠ·Π΅ ΡΠΎΠ»ΡΠΊΠΎ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΡ
ΠΆΠΈΡΠ½ΡΡ
ΠΊΠΈΡΠ»ΠΎΡ ΠΈ ΠΈΠ½Π΄Π΅ΠΊΡ HOMA-IR ΡΡΠ°Π»ΠΈ Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΠΌΠΈ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠ°ΠΌΠΈ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΈ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠ΅Π±ΡΠ²Π°Π½ΠΈΡ Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ΅.Π¦Π΅Π»Ρ. ΠΠ·ΡΡΠΈΡΡ ΠΌΠ°ΡΠΊΠ΅ΡΡ ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ ΠΈ ΠΈΡ
ΡΠ²ΡΠ·Ρ Ρ ΠΏΡΠ΅Π΄ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΠΌ ΡΡΠ°ΡΡΡΠΎΠΌ ΠΈ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΡΠΌΠΈ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡΠΌΠΈ ΠΊΠΎΡΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ (ΠΠ¨) Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ°Ρ
Π°ΡΠ½ΡΠΌ Π΄ΠΈΠ°Π±Π΅ΡΠΎΠΌ 2-Π³ΠΎ ΡΠΈΠΏΠ° (Π‘Π 2), ΠΏΡΠ΅Π΄ΠΈΠ°Π±Π΅ΡΠΎΠΌ ΠΈ Π½ΠΎΡΠΌΠΎΠ³Π»ΠΈΠΊΠ΅ΠΌΠΈΠ΅ΠΉ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 383 ΠΏΠΎΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΡΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
, ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΠΠ¨. ΠΡΠ΅ΠΌ ΡΡΠ°ΡΡΠ½ΠΈΠΊΠ°ΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ Π³Π»ΠΈΠΊΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΠ°ΡΡΡ ΠΏΠ΅ΡΠ΅Π΄ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠ΅ΠΉ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ ΡΡΠ²ΠΎΡΠΎΡΠΎΡΠ½ΡΠ΅ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΠ΅ ΠΆΠΈΡΠ½ΡΠ΅ ΠΊΠΈΡΠ»ΠΎΡΡ, ΠΈΠ½ΡΡΠ»ΠΈΠ½ Π½Π°ΡΠΎΡΠ°ΠΊ, Π³Π»ΡΠΊΠΎΠ·Π°, Π»ΠΈΠΏΠΈΠ΄Π½ΡΠΉ ΠΏΡΠΎΡΠΈΠ»Ρ ΠΈ ΡΠ°ΡΡΡΠΈΡΠ°Π½Ρ ΠΈΠ½Π΄Π΅ΠΊΡΡ ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎ-ΡΡΠΈ: HOMA-IR (Homeostasis Model Assessment of Insulin Resistance), QUICKI (Quantitative Insulin Sensitivity Check Index), Revised-QUICKI ΠΈ McAuley. ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΡΠ°Π·Π΄Π΅Π»Π΅Π½Ρ Π½Π° Π΄Π²Π΅ Π³ΡΡΠΏΠΏΡ: Π»ΠΈΡΠ° Ρ Π½Π°ΡΡΡΠ΅Π½ΠΈΡΠΌΠΈ ΡΠ³Π»Π΅Π²ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° (ΠΠ£Π), Π²ΠΊΠ»ΡΡΠ°Π²ΡΠΈΠΌΠΈ Π‘Π 2 ΠΈ ΠΏΡΠ΅Π΄ΠΈΠ°Π±Π΅Ρ (n = 192), ΠΈ Π±Π΅Π· ΠΠ£Π (n = 191). ΠΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ ΠΏΠ΅ΡΠΈΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ, ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΠ΅ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΡ ΠΈ ΠΈΡ
ΡΠ²ΡΠ·Ρ Ρ ΠΌΠ°ΡΠΊΠ΅ΡΠ°ΠΌΠΈ ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π‘Π²ΠΎΠ±ΠΎΠ΄Π½ΡΠ΅ ΠΆΠΈΡΠ½ΡΠ΅ ΠΊΠΈΡΠ»ΠΎΡΡ ΠΈ ΡΠ°ΡΡΠ΅ΡΠ½ΡΠ΅ ΠΈΠ½Π΄Π΅ΠΊΡΡ ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ HOMA-IR, QUICKI, Revised-QUICKI, McAuley ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π»ΠΈ Ρ ΠΏΠ΅ΡΠΈΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ: Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ ΠΈ ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΡ, Π»ΠΈΠΏΠΈΠ΄Π°ΠΌΠΈ, ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΠΊΠΎΠ°Π³ΡΠ»ΠΎΠ³ΡΠ°ΠΌΠΌΡ, ΡΠ°Π·ΠΌΠ΅ΡΠ°ΠΌΠΈ Π»Π΅Π²ΠΎΠ³ΠΎ ΠΏΡΠ΅Π΄ΡΠ΅ΡΠ΄ΠΈΡ, Π΄ΠΈΠ°ΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠ΅ΠΉ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΈ Π΄ΡΡΠ³ΠΈΠΌΠΈ. ΠΡΠΈ Π°Π½Π°Π»ΠΈΠ·Π΅ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΡΠ°ΡΡΠΎΡΠ° ΠΏΠΎΡΠ»Π΅ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΈΠ½ΡΡΠ»ΡΡΠ° (p = 0,044) ΠΈ ΠΏΡΠ΅Π±ΡΠ²Π°Π½ΠΈΡ Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ΅ ΠΏΠΎΡΠ»Π΅ ΠΠ¨ >30 Π΄Π½Π΅ΠΉ (p = 0,014) Π±ΡΠ»Π° Π·Π½Π°ΡΠΈΠΌΠΎ Π²ΡΡΠ΅ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠ£Π. ΠΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠ°ΠΌΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΊΠΎΠ½Π΅ΡΠ½ΠΎΠΉ ΡΠΎΡΠΊΠΈ (Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΡ ΠΏΠΎΡΠ»Π΅ ΠΠ¨ >10 Π΄Π½Π΅ΠΉ ΠΈ/ΠΈΠ»ΠΈ Π·Π½Π°ΡΠΈΠΌΠΎΠ΅ ΠΏΠ΅ΡΠΈΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ΅ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠ΅) ΠΏΠΎ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ ΠΌΠ½ΠΎΠ³ΠΎΡΠ°ΠΊΡΠΎΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΡΡΠ°Π»ΠΈ ΠΆΠ΅Π½ΡΠΊΠΈΠΉ ΠΏΠΎΠ» (ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠ°Π½ΡΠΎΠ² (ΠΠ¨) 2,862, 95% Π΄ΠΎΠ²Π΅ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΠΈΠ½ΡΠ΅ΡΠ²Π°Π» (ΠΠ) 1,062β7,712; p = 0,036), Π²ΠΎΠ·ΡΠ°ΡΡ (ΠΠ¨ 1,085, 95% ΠΠ 1,027β1,147; p = 0,003), Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΈΡΠΊΡΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΠΎΠ±ΡΠ°ΡΠ΅Π½ΠΈΡ (ΠΠ¨ 1,146, 95% ΠΠ 1,008β1,301; p = 0,035), ΠΈΠ½Π΄Π΅ΠΊΡ ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° (ΠΠ¨ 1,125, 95% ΠΠ 1,035β1,222; p = 0,005), ΡΠ°Π·ΠΌΠ΅ΡΡΒ Π»Π΅Π²ΠΎΠ³ΠΎΒ ΠΏΡΠ΅Π΄ΡΠ΅ΡΠ΄ΠΈΡΒ (ΠΠ¨Β 5,916,Β 95%Β ΠΠΒ 2,188β15,996; Ρ<0,001), Π»ΡΠ±ΠΎΠ΅ ΠΠ£Π (ΠΠ¨ 1,436, 95% ΠΠ 1,029β2,003; p = 0,032), Π‘Π 2 (ΠΠ¨ 2,184, 95% ΠΠ 1,087β4,389; p = 0,027), ΡΡΠΎΠ²Π΅Π½Ρ Π‘ΠΠ (ΠΠ¨ 5,707, 95% ΠΠ 1,183β27,537; p = 0,029) ΠΈ ΠΈΠ½Π΄Π΅ΠΊΡ HOMA-IR (ΠΠ¨ 1,164, 95% ΠΠ 1,025β1,322; p = 0,019).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π‘Π²ΠΎΠ±ΠΎΠ΄Π½ΡΠ΅ ΠΆΠΈΡΠ½ΡΠ΅ ΠΊΠΈΡΠ»ΠΎΡΡ, ΠΈΠ½Π΄Π΅ΠΊΡΡ ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ HOMA-IR, QUICKI, Revised-QUICKI, McAuley ΠΊΠΎΡΡΠ΅Π»ΠΈΡΡΡΡ ΡΠΎ ΠΌΠ½ΠΎΠΆΠ΅ΡΡΠ²ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠΎΠ΄Π²Π΅ΡΠ³Π°ΡΡΠΈΡ
ΡΡ ΠΠ¨, Π½ΠΎ Π² ΠΌΠ½ΠΎΠ³ΠΎΡΠ°ΠΊΡΠΎΡΠ½ΠΎΠΌ Π°Π½Π°Π»ΠΈΠ·Π΅ ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΎΡΠ°ΠΌΠΈ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΈ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ Π³ΠΎΡΠΏΠΈΡΠ°Π»ΠΈΠ·Π°ΡΠΈΠΈ ΡΡΠ°Π»ΠΈ Π»ΠΈΡΡ ΡΡΠΎΠ²Π΅Π½Ρ ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΡΡ
ΠΆΠΈΡΠ½ΡΡ
ΠΊΠΈΡΠ»ΠΎΡ ΠΈ HOMA-IR
Π€Π°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΡΡΠ½Π° ΡΡΠΈΠΌΡΠ»ΡΡΡΡ ΡΠΈΠ½ΡΠ΅Π·Ρ ΠΏΡΠΎΡΡΠΎΠΌΠ±ΡΠ½Ρ β Π½ΠΎΠ²ΠΈΠΉ ΠΏΡΠ΄Ρ ΡΠ΄ Π΄ΠΎ Π»ΡΠΊΡΠ²Π°Π½Π½Ρ ΡΠ΅ΡΠΎΠΊΠ°ΠΌβΡΠ½ΠΎΡ Ρ Π²ΠΎΡΠΎΠ±ΠΈ
The aim of the investigation is to study the effect of menadione sodium bisulfite on the course of experimental urolithiasis. Experimental urolithiasis was simulated in two groups of rats via consuming 1 % ethylene glycol solution as a drink during 6 weeks. The first group served as a control. Menadione sodium bisulfite was introduced subcutaneously in a dose of 500 mkg/kg daily in the second group, starting from the third week. The authors implemented a determination of the indices of the renal excretory function, a measurement of the activity of marker enzymes and the process of free radical oxidation, as well as a morphometric study of renal sections. It has been established that menadione sodium bisulfate relieves essentially the course of urolithiasis.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΈΠ·ΡΡΠΈΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ ΠΌΠ΅Π½Π°Π΄ΠΈΠΎΠ½Π° Π½Π°ΡΡΠΈΡ Π±ΠΈΡΡΠ»ΡΡΠΈΡΠ° Π½Π° ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΌΠΎΡΠ΅ΠΊΠ°ΠΌΠ΅Π½Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ. ΠΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½Π°Ρ ΠΌΠΎΡΠ΅ΠΊΠ°ΠΌΠ΅Π½Π½Π°Ρ Π±ΠΎΠ»Π΅Π·Π½Ρ ΠΌΠΎΠ΄Π΅Π»ΠΈΡΠΎΠ²Π°Π»Π°ΡΡ Ρ Π΄Π²ΡΡ
Π³ΡΡΠΏΠΏ ΠΊΡΡΡ ΠΏΡΡΠ΅ΠΌ ΠΏΠΎΡΡΠ΅Π±Π»Π΅Π½ΠΈΡ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 6 Π½Π΅Π΄Π΅Π»Ρ 1 % ΡΠ°ΡΡΠ²ΠΎΡΠ° ΡΡΠΈΠ»Π΅Π½Π³Π»ΠΈΠΊΠΎΠ»Ρ Π² Π²ΠΈΠ΄Π΅ ΠΏΠΈΡΡΡ. ΠΠ΅ΡΠ²Π°Ρ Π³ΡΡΠΏΠΏΠ° ΡΠ²Π»ΡΠ»Π°ΡΡ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ. ΠΠΎ Π²ΡΠΎΡΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅, Π½Π°ΡΠΈΠ½Π°Ρ Ρ ΡΡΠ΅ΡΡΠ΅ΠΉ Π½Π΅Π΄Π΅Π»ΠΈ, Π΅ΠΆΠ΅Π΄Π½Π΅Π²Π½ΠΎ Π²Π²ΠΎΠ΄ΠΈΠ»ΡΡ ΠΏΠΎΠ΄ΠΊΠΎΠΆΠ½ΠΎ ΠΌΠ΅Π½Π°Π΄ΠΈΠΎΠ½Π° Π½Π°ΡΡΠΈΡ Π±ΠΈΡΡΠ»ΡΡΠΈΡ Π² Π΄ΠΎΠ·Π΅ 500 ΠΌΠΊΠ³/ΠΊΠ³. ΠΡΡΡΠ΅ΡΡΠ²Π»ΡΠ»ΠΎΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΠΊΡΠΊΡΠ΅ΡΠΎΡΠ½ΠΎΠΉ ΡΡΠ½ΠΊΡΠΈΠΈ ΠΏΠΎΡΠ΅ΠΊ, ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠ΅ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠ½ΡΡ
ΡΠ΅ΡΠΌΠ΅Π½ΡΠΎΠ² ΠΈ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΡΠ²ΠΎΠ±ΠΎΠ΄Π½ΠΎ-ΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΠΊΠΈΡΠ»Π΅Π½ΠΈΡ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΌΠΎΡΡΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΡΠ΅ΡΠ½ΡΡ
ΡΡΠ΅Π·ΠΎΠ². Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΌΠ΅Π½Π°Π΄ΠΈΠΎΠ½Π° Π½Π°ΡΡΠΈΡ Π±ΠΈΡΡΠ»ΡΡΠΈΡ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΠΎΠ±Π»Π΅Π³ΡΠ°Π΅Ρ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΌΠΎΡΠ΅ΠΊΠ°ΠΌΠ΅Π½Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ.ΠΠ΅ΡΠ° Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ β Π²ΠΈΠ²ΡΠΈΡΠΈ Π²ΠΏΠ»ΠΈΠ² ΠΌΠ΅Π½Π°Π΄ΡΠΎΠ½Ρ Π½Π°ΡΡΡΡ Π±ΡΡΡΠ»ΡΡΡΡΡ Π½Π° ΠΏΠ΅ΡΠ΅Π±ΡΠ³ Π΅ΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΡ ΡΠ΅ΡΠΎΠΊΠ°ΠΌβΡΠ½ΠΎΡ Ρ
Π²ΠΎΡΠΎΠ±ΠΈ. ΠΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½Π° ΡΠ΅ΡΠΎΠΊΠ°ΠΌβΡΠ½Π° Ρ
Π²ΠΎΡΠΎΠ±Π° ΠΌΠΎΠ΄Π΅Π»ΡΠ²Π°Π»Π°ΡΡ Ρ Π΄Π²ΠΎΡ
Π³ΡΡΠΏ ΡΡΡΡΠ² ΡΠ»ΡΡ
ΠΎΠΌ ΡΠΏΠΎΠΆΠΈΠ²Π°Π½Π½Ρ ΠΏΡΠΎΡΡΠ³ΠΎΠΌ 6 ΡΠΈΠΆΠ½ΡΠ² 1 % ΡΠΎΠ·ΡΠΈΠ½Ρ Π΅ΡΠΈΠ»Π΅Π½Π³Π»ΡΠΊΠΎΠ»Ρ Ρ Π²ΠΈΠ³Π»ΡΠ΄Ρ ΠΏΠΈΡΡΡ. ΠΠ΅ΡΡΠ° Π³ΡΡΠΏΠ° Π±ΡΠ»Π° ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΡ. Π£ Π΄ΡΡΠ³ΡΠΉ Π³ΡΡΠΏΡ, ΠΏΠΎΡΠΈΠ½Π°ΡΡΠΈ Π· ΡΡΠ΅ΡΡΠΎΠ³ΠΎ ΡΠΈΠΆΠ½Ρ, ΡΠΎΠ΄Π½Ρ ΡΠ²ΠΎΠ΄ΠΈΠ²ΡΡ ΠΏΡΠ΄ΡΠΊΡΡΠ½ΠΎ ΠΌΠ΅Π½Π°Π΄ΡΠΎΠ½Ρ Π½Π°ΡΡΡΡ Π±ΡΡΡΠ»ΡΡΡΡ Ρ Π΄ΠΎΠ·Ρ 500 ΠΌΠΊΠ³ / ΠΊΠ³. ΠΠ΄ΡΠΉΡΠ½ΡΠ²Π°Π»ΠΎΡΡ Π²ΠΈΠ·Π½Π°ΡΠ΅Π½Π½Ρ ΠΏΠΎΠΊΠ°Π·Π½ΠΈΠΊΡΠ² Π΅ΠΊΡΠΊΡΠ΅ΡΠΎΡΠ½ΠΎΡ ΡΡΠ½ΠΊΡΡΡ Π½ΠΈΡΠΎΠΊ, Π²ΠΈΠΌΡΡΡΠ²Π°Π½Π½Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΌΠ°ΡΠΊΠ΅ΡΠ½ΠΈΡ
ΡΠ΅ΡΠΌΠ΅Π½ΡΡΠ² Ρ ΠΏΡΠΎΡΠ΅ΡΡ Π²ΡΠ»ΡΠ½ΠΎΡΠ°Π΄ΠΈΠΊΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΎΠΊΠΈΡΠ½Π΅Π½Π½Ρ, Π° ΡΠ°ΠΊΠΎΠΆ ΠΌΠΎΡΡΠΎΠΌΠ΅ΡΡΠΈΡΠ½Ρ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π½ΠΈΡΠΊΠΎΠ²ΠΈΡ
Π·ΡΡΠ·ΡΠ². ΠΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΠΎ ΠΌΠ΅Π½Π°Π΄ΡΠΎΠ½Ρ Π½Π°ΡΡΡΡ Π±ΡΡΡΠ»ΡΡΡΡ ΡΡΡΠΎΡΠ½ΠΎ ΠΏΠΎΠ»Π΅Π³ΡΡΡ ΠΏΠ΅ΡΠ΅Π±ΡΠ³ Π΅ΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΠΎΡ ΡΠ΅ΡΠΎΠΊΠ°ΠΌβΡΠ½ΠΎΡ Ρ
Π²ΠΎΡΠΎΠ±ΠΈ